Table 2.
Predictors of fibrosis clearance in SVR cases (n = 59) among the entire cohort (n = 85).
| Variable | n | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|
| OR (95% CI) | p-value | OR (95% CI) | p-value | ||
| Baseline characteristics | |||||
| PegIFN-α, 2a versus 2b | 43 versus 16 | 0.990 (0.227–4.315) | 0.990 | ||
| Sex, male versus female | 29 versus 30 | 0.833 (0.224–3.103) | 0.786 | ||
| Age, <48 versus ⩾48 | 8 versus 51 | 6.286 (1.270–31.102) | 0.024* | 4.592 (0.306–68.994) | 0.270 |
| METAVIR scores | |||||
| Fibrosis stages, <2 versus ⩾2 | 21 versus 38 | 7.179 (1.648–31.279) | 0.009* | 7.877 (1.076–57.637) | 0.042* |
| Activity grades, <2 versus ⩾2 | 48 versus 11 | 2.632 (0.300–23.058) | 0.382 | ||
| Steatosis scores, 0 versus ⩾1 | 17 versus 42 | 1.538 (0.386–6.137) | 0.542 | ||
| Diabetes mellitus, (–) versus (+) | 40 versus 19 | 0.795 (0.202–3.136) | 0.744 | ||
| HCV RNA (106 copies/ml) | |||||
| ⩽2 versus >2 | 31 versus 28 | 0.705 (0.189–2.628) | 0.603 | ||
| ⩽3 versus >3 | 33 versus 26 | 0.933 (0.250–3.482) | 0.918 | ||
| AST (U/l) | |||||
| ⩽40 versus >40 | 14 versus 44 | 1.227 (0.277–5.439) | 0.787 | ||
| ⩽80 versus >80 | 36 versus 22 | 0.680 (0.180–2.565) | 0.569 | ||
| ALT (U/l) | |||||
| ⩽55 versus >55 | 15 versus 43 | 0.581 (0.110–3.057) | 0.522 | ||
| ⩽110 versus >110 | 37 versus 21 | 0.992 (0.253–3.883) | 0.990 | ||
| Total bilirubin (mg/dl), ⩽1.2 versus >1.2 | 46 versus 12 | 0.632 (0.139–2.867) | 0.552 | ||
| Albumin (g/dl), ⩾4.4 versus <4.4 | 26 versus 31 | 0.623 (0.160–2.424) | 0.495 | ||
| Platelet counts (103/µl), ⩾170 versus <170 | 22 versus 36 | 6.286 (1.450–27.250) | 0.014* | 3.131 (0.436–22.478) | 0.256 |
| AFP (ng/ml), <4 versus ⩾4 | 18 versus 40 | 1.347 (0.339–5.345) | 0.672 | ||
| Glucose (mg/dl), ⩽105 versus >105 | 32 versus 24 | 0.556 (0.147–2.097) | 0.386 | ||
| HbA1c (%), <5.7 versus ⩾5.7 | 22 versus 31 | 0.541 (0.123–2.379) | 0.417 | ||
| HDL (mg/dl), ⩾40 versus <40 | 34 versus 19 | 0.972 (0.244–3.869) | 0.968 | ||
| LDL (mg/dl), ⩾135 versus <135 | 8 versus 45 | 5.429 (1.092–26.977) | 0.039* | 1.668 (0.106–26.177) | 0.716 |
| Biochemical changes | |||||
| Baseline versus 12 weeks after baseline | |||||
| AFP levels declining from ⩾4 to <4 ng/ml, (+) versus (–) | 8 versus 43 | 6.167 (1.205–31.550) | 0.029* | 3.562 (0.348–36.474) | 0.285 |
| Baseline versus EOS | |||||
| AST levels declining by >70%, (+) versus (–) | 19 versus 39 | 5.104 (1.268–20.544) | 0.022* | 9.013 (1.130–71.896) | 0.038* |
(1) To calculate the OR, each variable was categorized into a binary form with the latter designated as the reference factor. (2) For each variable, cases with missing data were excluded from both univariate and multivariate analysis. (3) Variables entered into multivariate analysis were those showing a p-value <0.05 in univariate analysis. (4) Additional data can be found in Supplementary Tables S4 and S5 online. AFP, alpha-fetoprotein; ALT, alanine transaminase; AST, aspartate transaminase; CI, confidence interval; EOS, end of surveillance; HbA1c, hemoglobin A1c; HCV, hepatitis C virus; HDL, high-density lipoprotein; LDL, low-density lipoprotein; OR, odds ratio; PegIFN, pegylated interferon; RNA, ribonucleic acid.
Binary logistic regression: A p-value <0.05 was considered statistically significant.
Bold values represent statistical significance in univariate or multivariate analysis.